The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.

中文翻译：

---

美国首例CAR T细胞疗法获得批准

第一种嵌合抗原受体T细胞疗法tisagenlecleucel已获得FDA的批准，可用于治疗对标准疗法无反应或至少复发两次的B细胞前体急性淋巴细胞白血病的25岁以下患者。